While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation.

2025

At the 2025 conference, the company detailed the company’s performance during the first three quarters of 2024. According to the CFO, this success due to efforts to expand its clinical pipeline.

Later in the month, AstraZeneca would continue with these efforts by investing about $570 million to expand its clinical studies in the Toronto, Canada, area.¹

In a press release, AstraZeneca’s CEO Pascal Soriot said, “This investment is a reflection of our growing clinical pipeline, our strong belief in Canada’s potential as a global hub for life sciences innovation, and the value of public-private collaboration with the Ontario government. We believe the diverse talent pool together with the network of world-class universities, hospitals, and research centers will help us bring new medicines to Canadians and patients worldwide.”

Doug Ford, Premier of Ontario, added, “Today’s announcement is fantastic news for Ontario and another testament to the incredible talent, innovation and opportunities our province has to offer. Our government, through Invest Ontario, is proud to support AstraZeneca with C$16.1 million to help bring these hundreds of new, highly-skilled jobs to Ontario, strengthening Ontario’s position as a global leader in life sciences and innovation.”

In the same release, Gaby Bourbara, president of AstraZeneca Canada, also said, “AstraZeneca’s continued investment in Ontario is crucial to advancing innovative medicines that treat, prevent, and may one day cure complex diseases like prostate, lung, and breast cancer, as well as rare diseases. AstraZeneca’s investment of C$820 million (US$570m), alongside the Government of Ontario’s contribution through Invest Ontario, will strengthen the Province’s life sciences strategy, driving economic growth, and foster innovation that benefits patients in Canada and around the world.”

2024

In 2024, AstraZeneca’s presentation actually focused on plans that company had to expand its business through the year 2030. In order to achieve its goals, the company plans to introduce a number of new potentially blockbuster treatments to the market by the end of the decade.

Around the same time, AstraZeneca announced that FDA had granted Enhertu priority review to treat metastatic HER2-positive solid tumors.²

At the time, Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, said, “Today’s Priority Review for the first tumor-agnostic submission for Enhertu reflects the potential of this medicine to redefine the treatment of HER2-expressing cancers. Biomarkers for HER2 expression are already established in breast and gastric cancers, but we must now define them across tumor types. We will continue working closely with the FDA to bring this potential first tumor-agnostic HER2-targeted medicine and biomarker to patients as quickly as possible.”

Ken Takeshita, MD, global head of R&D at Daiichi Sankyo, added, “The clinical benefit seen across HER2-expressing metastatic solid tumors in the DESTINY-PanTumor02 trial and ongoing data from the Enhertu clinical development program continues to demonstrate the potential of this medicine beyond its approved indications. If approved, Enhertu could become the first HER2-directed therapy and antibody drug conjugate with a tumor-agnostic indication, providing patients with a potential new treatment option.”

AstraZeneca also announced regulatory approval in Japan for Voydeya, a treatment for PNH.³

In a press release issued at the time, Alexion CEO Marc Donoyer said, “More than 20 years of PNH research has cemented the role of C5 inhibition in effectively treating this rare disease, and we continue to innovate for this community. Voydeya, as add-on to standard-of-care, is a testament to our determination to address the needs of those impacted by clinically significant EVH without disruption to proven therapy. We look forward to bringing this important advancement to the subset of PNH patients in Japan who are living with this condition.”

Sources

1. AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery. AstraZeneca. January 23, 2025. Accessed December 12, 2025. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-c820-million-us570m-investment-in-canada-to-advance-growing-global-hub-and-clinical-delivery.html
2. Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours. AstraZeneca. January 29, 2024. Accessed December 12, 2025. https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours.html
3. Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy. AstraZeneca. January 19, 2024. Accessed December 12, 2025. https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-danicopan-granted-first-ever-regulatory-approval-in-japan-for-adults-with-pnh-to-be-used-in-combination-with-c5-inhibitor-therapy.html